Remove 2017 Remove Chemotherapy Remove Immunization
article thumbnail

First CAR T-cell therapy recommended on NHS

European Pharmaceutical Review

CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells. Of those who receive a transplant, about 50 percent will ultimately relapse, stated research from 2017, published in the journal Blood. Could CAR T therapies be manufactured in one day?

article thumbnail

NK cell immunotherapy: what’s next in clinical development?

European Pharmaceutical Review

He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Transforming oncology with antibody therapeutics

European Pharmaceutical Review

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. 2017; 8(43): 75712–26.

article thumbnail

Merck pulls Keytruda’s FDA nod for third-line stomach cancer

pharmaphorum

Merck’s drug has been approved for this use since 2017, but failed to show a statistically significant improvement over third-line chemotherapy in either of two confirmatory trials – KEYNOTE-061 and KEYNOTE-062. The data means that immunotherapy has now moved earlier in the treatment pathway.

FDA 52
article thumbnail

Progressing personalised cell therapies in oncology

European Pharmaceutical Review

Since 2017, six CAR-T cell therapies have been approved by the US Food and Drug Administration (FDA) for the treatment of blood cancers, including lymphomas, some forms of leukaemia, and, most recently, multiple myeloma. CAR T Cells: Engineering Immune Cells to Treat Cancer [Internet]. References National Cancer Institute. Cancer.gov.

article thumbnail

The top 5 pharma M&A deals of 2020

pharmaphorum

California-based Gilead announced its strong intentions in oncology in 2017 with its $11.9 months in patients treated with chemotherapy. Sanofi’s acquisition builds on a partnership to develop central nervous system drugs that began in late 2017. billion (see below). months, compared with 6.7 Johnson and Johnson & Momenta.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

Granzyme B is an enzyme released by activated immune cells and using this as a in vivo imaging biomarker has great potential to monitor immune cell activation in a variety of inflammatory diseases, autoimmune diseases, cancer and infections. What do you envision the future of radiopharmaceuticals to be like? Internet] Jaafar-Thiel, L.